Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT02823262 | A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older | terminated | N/A | 65 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT03480659 | Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC | terminated | — | 165 | HKGepitherapeuticsINDUSTRY | 1 | Dec 21, 2023 | clinicaltrials |
| NCT04714619 | CB-103 Plus NSAI In Luminal Advanced Breast Cancer(CAILA) | terminated | Phase 2 | 2 | MedSIROTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT00679029 | Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer | terminated | Phase 2 | 15 | University of NebraskaOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT06161792 | Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer(VMS) | terminated | Phase 2 | 10 | Yung Shin Pharm. Ind. Co., Ltd.INDUSTRY | 1 | Dec 8, 2023 | clinicaltrials |
| NCT02642094 | Aging Mammary Stem Cells and Breast Cancer Prevention | terminated | Phase 2 | 58 | LuZhe SunOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer(TARA) | terminated | Phase 2 | 1 | Mylin A. Torres, MDOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | terminated | Phase 1 | 10 | Leap Therapeutics, Inc.INDUSTRY | 1 | Nov 30, 2023 | clinicaltrials |
| NCT02963363 | Adapted Physical Activity for Breast Cancer HER2 Positive Patient(APACAN2) | terminated | N/A | 36 | Centre Jean PerrinOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01990352 | Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy | terminated | Phase 2 | 24 | University of ArizonaOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT01931709 | FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer | terminated | N/A | 35 | University of WashingtonOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02127073 | Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer | terminated | Phase 2 | 8 | Montefiore Medical CenterOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT04149522 | Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer | terminated | Phase 2 | 40 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT03931655 | Photoacoustic Lymph Node Imaging | terminated | — | 1 | Geoff LukeOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04932031 | Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy(SENSE) | terminated | — | 123 | Sapere BioINDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT03786094 | Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer(FORTRESS) | terminated | Phase 3 | 432 | Spexis AGINDUSTRY | 13 | Nov 1, 2023 | clinicaltrials |
| NCT00019643 | Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer | terminated | — | 26 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02626377 | Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté(ICE) | terminated | N/A | 186 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03623490 | Optimizing the Management of Patients With Oral Therapy(IPAC) | terminated | N/A | 101 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05414123 | A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide(FORESEE) | terminated | — | 40 | Biocept, Inc.INDUSTRY | 1 | Oct 16, 2023 | clinicaltrials |
| NCT04562233 | Breast Cancer and Resistance Exercise Program(B-REP) | terminated | N/A | 56 | Rutgers, The State University of New JerseyOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT04625517 | Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM) | terminated | Phase 4 | 6 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT03190967 | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2023 | clinicaltrials |
| NCT01873833 | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 10 | University of Southern CaliforniaOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT03916068 | Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy | terminated | Phase 2 | 1 | Legacy Health SystemOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04139993 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | terminated | Phase 1 | 3 | Mayo ClinicOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT01276704 | Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer | terminated | Phase 2 | 180 | Carol Fabian, MDOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | terminated | — | 20 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | terminated | Phase 1 | 5 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00934895 | Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca | terminated | Phase 1 / Phase 2 | 27 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT00665457 | Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery | terminated | Phase 2 | 3 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 12 | NBE-Therapeutics AGINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT02585388 | Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.(CHEOPS) | terminated | Phase 2 | 120 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT01975597 | Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer | terminated | — | 8 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT04720664 | Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer(OASIS) | terminated | Phase 2 | 11 | Georgetown UniversityOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT04385433 | A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer(PRAVAPREV-01) | terminated | Phase 3 | 15 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 2 | Aug 24, 2023 | clinicaltrials |
| NCT03329378 | Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer | terminated | Phase 2 | 7 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04092816 | Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention(FAMILY) | terminated | N/A | 15 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | terminated | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT01712815 | PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer | terminated | N/A | 12 | University of Southern CaliforniaOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT00765765 | Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 6 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT04936451 | Electrotherapy in the Management of Myofascial Syndrome(MODYMYO) | terminated | N/A | 5 | Institut Cancerologie de l'OuestOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT05428709 | Women In Steady Exercise Research - Window of Opportunity for Exercise and Tumor Biology(WISER-WIN) | terminated | N/A | 3 | Milton S. Hershey Medical CenterOTHER | 1 | Jul 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 16, 2024source: clinicaltrials